Tuberous sclerosis--also called tuberous sclerosis complex (TSC)1--is a rare, multi-system genetic disease that causes benign tumors to grow in the brain and on other vital organs such as the kidneys, heart, eyes, lungs, and skin. It usually affects the central nervous system and results in a combination of symptoms including seizures, developmental delay, behavioral problems, skin abnormalities, and kidney disease.
The disorder affects as many as 25,000 to 40,000 individuals in the United States and about 1 to 2 million individuals worldwide, with an estimated prevalence of one in 6,000 newborns. TSC occurs in all races and ethnic groups, and in both genders.
The name tuberous sclerosis comes from the characteristic tuber or potato-like nodules in the brain, which calcify with age and become hard or sclerotic. The disorder--once known as epiloia or Bourneville's disease--was first identified by a French physician more than 100 years ago.
Many TSC patients show evidence of the disorder in the first year of life. However, clinical features can be subtle initially, and many signs and symptoms take years to develop. As a result, TSC can be unrecognized or misdiagnosed for years.
TSC is caused by defects, or mutations, on two genes-TSC1 and TSC2. Only one of the genes needs to be affected for TSC to be present. The TSC1 gene, discovered in 1997, is on chromosome 9 and produces a protein called hamartin. The TSC2 gene, discovered in 1993, is on chromosome 16 and produces the protein tuberin. Scientists believe these proteins act in a complex as growth suppressors by inhibiting the activation of a master, evolutionarily conserved kinase called mTOR. Loss of regulation of mTOR occurs in cells lacking either hamartin or tuberin, and this leads to abnormal differentiation and development, and to the generation of enlarged cells, as are seen in TSC brain lesions.
Although some individuals inherit the disorder from a parent with TSC, most cases occur as sporadic cases due to new, spontaneous mutations in TSC1 or TSC2. In this situation, neither parent has the disorder or the faulty gene(s). Instead, a faulty gene first occurs in the affected individual.
In familial cases, TSC is an autosomal dominant disorder, which means that the disorder can be transmitted directly from parent to child. In those cases, only one parent needs to have the faulty gene in order to pass it on to a child. If a parent has TSC, each offspring has a 50 percent chance of developing the disorder. Children who inherit TSC may not have the same symptoms as their parent and they may have either a milder or a more severe form of the disorder.
Rarely, individuals acquire TSC through a process called gonadal mosaicism. These patients have parents with no apparent defects in the two genes that cause the disorder. Yet these parents can have a child with TSC because a portion of one of the parent's reproductive cells (sperm or eggs) can contain the genetic mutation without the other cells of the body being involved. In cases of gonadal mosaicism, genetic testing of a blood sample might not reveal the potential for passing the disease to offspring.
TSC can affect many different systems of the body, causing a variety of signs and symptoms. Signs of the disorder vary depending on which system and which organs are involved. The natural course of TSC varies from individual to individual, with symptoms ranging from very mild to quite severe. In addition to the benign tumors that frequently occur in TSC, other common symptoms include seizures, mental retardation, behavior problems, and skin abnormalities. Tumors can grow in nearly any organ, but they most commonly occur in the brain, kidneys, heart, lungs, and skin. Malignant tumors are rare in TSC. Those that do occur primarily affect the kidneys.
Brain involvement in TSC Three types of brain lesions are seen in TSC: cortical tubers, for which the disease is named, generally form on the surface of the brain but may also appear in the deep areas of the brain: subependymal nodules (SEN), which form in the walls of the ventricles--the fluid-filled cavities of the brain; and subependymal giant-call astrocytomas (SEGA), which develop from SEN and grow such that they may block the flow of fluid within the brain, causing a buildup of fluid and pressure and leading to headaches and blurred vision.
TSC usually causes the greatest problems for those affected and their family members through effects on brain function. Most individuals with TSC will have seizures at some point during their life. Seizures of all types may occur, including infantile spasms; tonic-clonic seizures (also known as grand mal seizures); or tonic, akinetic, atypical absence, myoclonic, complex partial or generalized squires. Infantile spasms can occur as soon as the day of birth and are often difficult to recognize. Seizures can also be difficult to control by medication,and sometimes surgery or other measures are used.
Abut one-half to two-thirds of individuals with TSC have developmental delays ranging from mild learning disabilities to severe mental retardation. Behavior problems, including aggression, sudden rage, attention deficit hyperactivity disorder, acting out, obsessive-compulsive disorder, and repetitive, destructive, or self-harming behavior occur in children with TSC and can be difficult to manage. About one-third of children with TSC meet criteria for autism spectrum disorder.
Kidney problems such as cysts and angiomyolipomas occur in an estimated 70 to 80 percent of individuals with TSC, usually occurring between ages 15 and 30. Cysts are usually small, appear in limited numbers, and cause no serious problems. Approximately 2 percent of individuals with TSC develop large numbers of cysts in a pattern similar to polycystic kidney disease2 during childhood. In these cases, kidney function is compromised and kidney failure occurs. In rare instances, the cysts may bleed, leading to blood loss and anemia.
Angiomyolipomas-benign growths consisting of fatty tissue and muscle cells-are the most common kidney lesions in TSC. These growths are seen in the majority ofindividuals with TSC, but are also found in about one of every 300 people without TSC. Angiomyolipomas caused by TSC are usually found in both kidneys and in most cases they produce no symptoms. However, they can sometimes grow so large that they cause pain or kidney failure. Bleeding from angiomyolipomas may also occur, causing both pain and weakness. If severe bleeding does not stop naturally, there may severe blood loss, resulting in profound anemia and a life-threatening drop in blood pressure, warranting urgent medical attention.
Other rare kidney problems include renal cell carcinoma, developing from an angiomyolipoma, and oncocytomas, benign tumors unique to individuals with TSC.
Tumors called cardiac rhabdomyomas are often found in the hearts of infants and young children with TSC, and they are often seen on prenatal fetus ultrasound exams. If the tumors are large or there are multiple tumors, they can block circulation and cause death. However, if they do not cause problems at birth-when in most cases they are at their largest size-they usually become smaller with time and do not affect the individual in later life.
Benign tumors called phakomas are sometimes found in the eyes of individuals with TSC, appearing as white patches on the retina. Generally they do not cause vision loss or other vision problems, but they can be used to help diagnose the disease.
Additional tumors and cysts may be found in other areas of the body, including the liver, lung, and pancreas. Bone cysts, rectal polyps, gum fibromas, and dental pits may also occur.
A wide variety of skin abnormalities may occur in individuals with TSC. Most cause no problems but are helpful in diagnosis. Some cases may cause disfigurement, necessitating treatment. The most common skin abnormalities include:
Lung lesions are present in about one-third of adult women with TSC and are much less commonly seen in men. Lung lesions
include lymphangioleiomyomatosis (LAM) and multinodular multifocal pneumocyte hyperplasia (MMPH). LAM is a tumor-like disorder
in which cells proliferate in the lungs, and there is lung destruction with cyst formation There is a range of symptoms
with LAM, with many TSC individuals having no symptoms, while others suffer with breathlessness, which can progress and be
severe. MMPH is a more benign tumor that occurs in men and women equally.
The diagnosis of TSC is based upon clinical criteria. In many cases the first clue to recognizing TSC is the presence of seizures or delayed development. In other cases, the first sign may be white patches on the skin (hypomelanotic macules) or the identification of cardiac tumor rhabdomyoma..
Diagnosis of the disorder is based on a careful clinical exam in combination with computed tomography (CT) or magnetic resonance imaging (MRI) of the brain, which may show tubers in the brain, and an ultrasound of the heart, liver, and kidneys, which may show tumors in those organs. Doctors should carefully examine the skin for the wide variety of skin features, the fingernails and toenails for ungual fibromas, the teeth and gums for dental pits and/or gum fibromas, and the eyes for retinal lesions. A Wood's lamp or ultraviolet light may be used to locate the hypomelantic macules which are sometimes hard to see on infants and individuals with pale or fair skin. Because of the wide variety of signs of TSC, it is best if a doctor experienced in the diagnosis of TSC evaluates a potential patient.
In infants TSC may be suspected if the child has cardiac rhabdomyomas or seizures (infantile spasms) at birth. With a careful examination of the skin and brain, it may be possible to diagnose TSC in a very young infant. However, many children are not diagnosed until later in life when their seizures begin and other symptoms such as facial angiofibromas appear.
There is no cure for TSC, although treatment is available for a number of the symptoms. Antiepileptic drugs may be used to control seizures. Vigabatrin is a particularly useful medication in TSC, and has been approved by the U.S. Food and Drug Administration (FDA) for treatment of infantile spams in TSC, although it has significant side effects. The FDA has approved the drug everolimus (Afinitor®) to treat subependymal giant cell astrocytomas (SEGA brain tumors) and angiomyolipoma kidney tumors. Specific medications may be prescribed for behavior problems. Intervention programs including special schooling and occupational therapy may benefit individuals with special needs and developmental issues. Surgery may be needed in case of complications connected to tubers, SEN or SEGA, as well as in risk of hemorrhage from kidney tumors. Respiratory insufficiency due to LAM can be treated with supplemental oxygen therapy or lung transplantation if severe.
Because TSC is a lifelong condition, individuals need to be regularly monitored by a doctor to make sure they are receiving the best possible treatments. Due to the many varied symptoms of TSC, care by a clinician experienced with the disorder is recommended.
Basic laboratory studies have revealed insight into the function of the TSC genes and has led to recent use of rapamycin and related drugs for treating some manifestations of TSC. Rapamycin has been shown to be effective in treating SEGA, the brain tumor seen in TSC. However, its benefit for a variety of other aspects of and tumors seen in people with TSC is less certain, and clinical trials looking at the benefit carefully are continuing. Rapamycin and related drugs are not yet approved by the FDA for any purpose in individuals with TSC.
The prognosis for individuals with TSC is highly variable and depends on the severity of symptoms. Tthose individuals with mild symptoms usually do well and have a normal life expectancy, while paying attention to TSC-specific issues. Individuals who are severely affected can suffer from severe mental retardation and persistent epilepsy.
All individuals with TSC are at risk for life-threatening conditions related to the brain tumors, kidney lesions, or LAM. Continued monitoring by a physician experienced with TSC is important. With appropriate medical care, most individuals with the disorder can look forward to normal life expectancy.
Within the Federal Government, the leading supporter of research on TSC is the National Institute of Neurological Disorders and Stroke (NINDS). The NINDS, part of the National Institutes of Health (NIH), is responsible for supporting and conducting research on the brain and the central nervous system. NINDS conducts research in its laboratories at NIH and also supports studies through grants to major medical institutions across the country. The National Heart, Lung, and Blood Institute and the National Cancer Institute, also components of the NIH, support and conduct research on TSC.
Scientists who study TSC seek to increase our understanding of the disorder by learning more about the TSC1 and TSC2 genes that can cause the disorder and the function of the proteins-tuberin and hamartin-produced by these genes. Scientists hope knowledge gained from their current research will improve the genetic test for TSC and lead to new avenues of treatment, methods of prevention, and, ultimately, a cure for this disorder.
Research studies run the gamut from very basic scientific investigation to clinical translational research. For example, some investigators are trying to identify all the protein components that are in the same 'signaling pathway' in which the TSC1 and TSC2 protein products and the mTOR protein are involved. Other studies are focused on understanding in detail how the disease develops, both in animal models and in patients, to better define new ways of controlling or preventing the development of the disease. Finally, clinical trials of rapamycin are underway (with NINDS and NCI support) to rigorously test the potential benefit of this compound for some of the tumors that are problematic in TSC patients.
1Tuberous sclerosis is often referred to as tuberous sclerosis complex (TSC) in medical literature to help distinguish it from
Tourette's syndrome, an unrelated neurological disorder.
2Polycystic kidney disease is a genetic disorder characterized by the growth of numerous fluid-filled cysts in the kidneys.
For more information on neurological disorders or research programs funded by the National Institute of Neurological Disorders and Stroke, contact the Institute's Brain Resources and Information Network (BRAIN) at:
P.O. Box 5801
Bethesda, MD 20824
Information also is available from the following organizations:
|Tuberous Sclerosis Alliance
801 Roeder Road
Silver Spring, MD 20910-4467
Tel: 301-562-9890 800-225-6872
8301 Professional Place East, Suite 200
Landover, MD 20785-7223
Tel: 301-459-3700 800-EFA-1000 (332-1000)
|National Organization for Rare Disorders (NORD)
55 Kenosia Avenue
Danbury, CT 06810
Tel: 203-744-0100 Voice Mail 800-999-NORD (6673)
NIH Publication No. 07-1846
Office of Communications and Public Liaison
National Institute of Neurological Disorders and Stroke
National Institutes of Health
Bethesda, MD 20892
NINDS health-related material is provided for information purposes only and does not necessarily represent endorsement by or an official position of the National Institute of Neurological Disorders and Stroke or any other Federal agency. Advice on the treatment or care of an individual patient should be obtained through consultation with a physician who has examined that patient or is familiar with that patient's medical history.
All NINDS-prepared information is in the public domain and may be freely copied. Credit to the NINDS or the NIH is appreciated.
Last updated February 23, 2015